Gilead Sciences News and Activities

Gilead Sciences is one of the...

• Forbes Global 2000 (#233);
• Fortune 500 (#153);
• Nasdaq 100;
• Russell 3000;
• S&P 500;
• TOB Iconic 10,000.

Gilead Sciences is a company listed under the stock ticker GILD (US).

Gilead Sciences has a direct presence in 8 countries.

Gilead Sciences has 10 subsidiaries including Arcellx, Gilead Sciences APAC and Gilead Sciences Canada.

They are in:

• Pharmaceuticals55%
• Biotechnology45%

Acquisition, funding and merger involving Gilead Sciences.

• Gilead Sciences has acquired Tubulis (posted on May 21 2026).
• Gilead Sciences has acquired Arcellx (posted on April 28 2026).
• Gilead Sciences has announced the acquisition of Tubulis  (posted on April 16 2026).
• Gilead Sciences has announced the acquisition of Ouro Medicines  (posted on March 24 2026).
• See more news about Gilead Sciences Hide news involving Gilead Sciences

View the org chart displaying its 181 main executives

Most searched biographies at Gilead Sciences

• Daniel O'Day, Chairman of the Board and Chief Executive Officer
• Kelly Kramer, Director
• Sandra Horning, Director

Popular executive movements at Gilead Sciences

• Divya Dhankhar has joined the company as Director, Global Digital Innovation and Artificial Intelligence  (posted on June 30 2026).
• Scott Nunn, Senior Director, Packaging and Labeling Development, has left the company  (posted on June 18 2026).
• Kimberly Jablonski has joined the company as Senior Vice President, Global Legal Business Partners  (posted on June 18 2026).

Click here to view some more movements at Gilead Sciences

Create your alert
to follow the executive moves at Gilead Sciences.

Gilead Sciences has 1,919 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• Catalyst Pharmaceuticals, listed under ticker CPRX, has been delisted. (posted on July 13 2026).
• Angelini Pharma has acquired Catalyst Pharmaceuticals (posted on July 13 2026).
• Vertex Pharmaceuticals has announced the acquisition of Crinetics Pharmaceuticals  (posted on July 7 2026).

Popular contacts in Pharmaceuticals

• David Ricks - President, Chief Executive Officer and Chairman of the Board at Eli Lilly
• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz

Learn more about the Pharmaceuticals industry

Press releases by Gilead Sciences

• Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
• Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase Primase Inhibitor Programs for Recurrent Genital Herpes
• First Clinical Data for Gileads Investigational Once Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
• Gilead Sciences to Present at Upcoming Investor Conferences
• Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025 Including an Investigational Long Acting Twice Yearly Therapy Option
• Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease AASLD Meeting 2024
• Late Breaking Clinical Data and Real World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
• Gilead Sciences Announces Third Quarter 2024 Financial Results
• Kite to Highlight Industry Leading CAR T Cell Therapy Portfolio at ASH 2024 Including Positive Survival Outcomes in Both Clinical Trials and the Real World
• Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
• View more press releases Close

Social media about Gilead Sciences

• Gilead Sciences on Wikipedia, Google News & Yahoo Finance
• Gilead Sciences on LinkedIn, X (Twitter) & YouTube